{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:03:19Z","timestamp":1789038199649,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12 CA076930"],"award-info":[{"award-number":["K12 CA076930"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA044991"],"award-info":[{"award-number":["P01 CA044991"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24 CA184039"],"award-info":[{"award-number":["K24 CA184039"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hutchinson Center\/University of Washington Cancer Consortium Cancer Center","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}]},{"name":"Frank and Betty Vandermeer"},{"name":"Don and Debbie Hunkins"},{"name":"Mary Aileen Wright Memorial Fund"},{"name":"David and Patricia Giuliani Family Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1111\/bjh.13773","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T02:09:11Z","timestamp":1444702151000},"page":"788-797","source":"Crossref","is-referenced-by-count":12,"title":["High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma"],"prefix":"10.1111","volume":"171","author":[{"given":"Ryan D.","family":"Cassaday","sequence":"first","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Hematology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A.","family":"Stevenson","sequence":"additional","affiliation":[{"name":"Clinical Statistics Division; Fred Hutchinson Cancer Research Center; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore A.","family":"Gooley","sequence":"additional","affiliation":[{"name":"Clinical Statistics Division; Fred Hutchinson Cancer Research Center; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Chauncey","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Veterans Affairs Puget Sound Health Care System; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine; Department of Radiology; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Philip","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Hematology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnnie J.","family":"Orozco","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Hematology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William I.","family":"Bensinger","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona A.","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Hematology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian J.","family":"Green","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward N.","family":"Libby","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle USA"},{"name":"Division of Medical Oncology; Department of Medicine; University of Washington; Seattle USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"10.1111\/bjh.13773-BIB0001|bjh13773-cit-0001","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.bbmt.2013.07.005","article-title":"Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation","volume":"19","author":"Cassaday","year":"2013","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1111\/bjh.13773-BIB0002|bjh13773-cit-0002","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2014.10.024","article-title":"Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation","volume":"21","author":"Cassaday","year":"2015","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1111\/bjh.13773-BIB0003|bjh13773-cit-0003","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0004|bjh13773-cit-0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1083-8791(03)70007-X","article-title":"BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective","volume":"9","author":"Cooney","year":"2003","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1111\/bjh.13773-BIB0005|bjh13773-cit-0005","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0006|bjh13773-cit-0006","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0007|bjh13773-cit-0007","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.16.8294","article-title":"High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation","volume":"26","author":"Devizzi","year":"2008","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0008|bjh13773-cit-0008","first-page":"542","article-title":"Current treatment standards and emerging strategies in mantle cell lymphoma","volume":"2009","author":"Dreyling","year":"2009","journal-title":"Hematology\/the Education Program of the American Society of Hematology American Society of Hematology Education Program"},{"key":"10.1111\/bjh.13773-BIB0009|bjh13773-cit-0009","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0010|bjh13773-cit-0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.2013.49.2454","article-title":"Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality","volume":"32","author":"Fenske","year":"2014","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0011|bjh13773-cit-0011","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2141.2007.06869.x","article-title":"High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory\/resistant B-cell non-Hodgkin lymphomas","volume":"139","author":"Ferrucci","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.13773-BIB0012|bjh13773-cit-0012","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0013|bjh13773-cit-0013","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0014|bjh13773-cit-0014","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2003-02-0622","article-title":"High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis","volume":"102","author":"Gopal","year":"2003","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0015|bjh13773-cit-0015","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1200\/JCO.2006.09.1215","article-title":"High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60\u00a0years old with relapsed or refractory B-cell lymphoma","volume":"25","author":"Gopal","year":"2007","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0016|bjh13773-cit-0016","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.bbmt.2014.02.004","article-title":"Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age >\/= 60\u00a0years with B cell lymphoma","volume":"20","author":"Gopal","year":"2014","journal-title":"Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1111\/bjh.13773-BIB0017|bjh13773-cit-0017","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0018|bjh13773-cit-0018","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1002\/cncr.26182","article-title":"Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia\/acute myelogenous leukemia","volume":"117","author":"Guidetti","year":"2011","journal-title":"Cancer"},{"key":"10.1111\/bjh.13773-BIB0019|bjh13773-cit-0019","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/sj.bmt.1704110","article-title":"Autologous stem cell transplantation for Hodgkin's disease: busulfan, melphalan and thiotepa compared to a radiation-based regimen","volume":"32","author":"Gutierrez-Delgado","year":"2003","journal-title":"Bone Marrow Transplantation"},{"key":"10.1111\/bjh.13773-BIB0020|bjh13773-cit-0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0021|bjh13773-cit-0021","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0022|bjh13773-cit-0022","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0023|bjh13773-cit-0023","first-page":"152","article-title":"Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma Patients included in the LyMa trial, a Lysa study","volume":"120","author":"Le Gouill","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1111\/bjh.13773-BIB0024|bjh13773-cit-0024","first-page":"146","article-title":"Rituximab maintenance versus wait and watch after four courses of R-DHAP followed by autologous stem cell transplantation in previously untreated young patients with mantle cell lymphoma: first interim analysis of the phase III prospective lyma trial, a Lysa study","volume":"124","author":"Gouill","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1111\/bjh.13773-BIB0025|bjh13773-cit-0025","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1200\/JCO.2004.06.016","article-title":"Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group","volume":"22","author":"Lenz","year":"2004","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0026|bjh13773-cit-0026","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0027|bjh13773-cit-0027","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJM199310213291702","article-title":"Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support","volume":"329","author":"Press","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/bjh.13773-BIB0028|bjh13773-cit-0028","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood.V96.9.2934","article-title":"A phase I\/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas","volume":"96","author":"Press","year":"2000","journal-title":"Blood"},{"key":"10.1111\/bjh.13773-BIB0029|bjh13773-cit-0029","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1111\/bjh.13773-BIB0030|bjh13773-cit-0030","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Shimoni","year":"2012","journal-title":"Cancer"},{"key":"10.1111\/bjh.13773-BIB0031|bjh13773-cit-0031","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499","volume":"30","author":"Smith","year":"2012","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0032|bjh13773-cit-0032","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s10985-008-9098-9","article-title":"Adjusted estimates for time-to-event endpoints","volume":"14","author":"Storer","year":"2008","journal-title":"Lifetime Data Analysis"},{"key":"10.1111\/bjh.13773-BIB0033|bjh13773-cit-0033","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","article-title":"Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial","volume":"31","author":"Vose","year":"2013","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0034|bjh13773-cit-0034","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2009.21.8545","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma","volume":"27","author":"Wang","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0035|bjh13773-cit-0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/bjh.13773-BIB0036|bjh13773-cit-0036","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","article-title":"Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15\u00a0Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"27","author":"Winter","year":"2009","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1111\/bjh.13773-BIB0037|bjh13773-cit-0037","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.7560","article-title":"Sequential radioimmunotherapy with tositumomab\/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Zelenetz","year":"2006","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13773","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjh.13773\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T08:48:48Z","timestamp":1625388528000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,12]]}},"URL":"https:\/\/doi.org\/10.1111\/bjh.13773","archive":["Portico"],"relation":{},"ISSN":["0007-1048"],"issn-type":[{"value":"0007-1048","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10,12]]}}}